MNG1027
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.515
- PROTEIN_SECRETION+0.471
- MITOTIC_SPINDLE+0.395
- UNFOLDED_PROTEIN_RESPONSE+0.375
- MYC_TARGETS_V1+0.372
- INTERFERON_GAMMA_RESPONSE+0.362
- MYC_TARGETS_V2+0.323
- G2M_CHECKPOINT+0.287
- UV_RESPONSE_DN+0.284
- E2F_TARGETS+0.273
Top 10 suppressed
- ANGIOGENESIS-0.445
- PANCREAS_BETA_CELLS-0.385
- TNFA_SIGNALING_VIA_NFKB-0.381
- KRAS_SIGNALING_DN-0.369
- COAGULATION-0.335
- ESTROGEN_RESPONSE_LATE-0.264
- SPERMATOGENESIS-0.253
- HYPOXIA-0.215
- KRAS_SIGNALING_UP-0.209
- COMPLEMENT-0.182
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1220 | — | — | 0.801 |
| 2 | 65567450-e04a-4251-9939-8d2545077236 | — | — | 0.784 |
| 3 | MNG819 | — | — | 0.784 |
| 4 | MNG240 | — | — | 0.781 |
| 5 | CBB97C4E-43C7-4257-A85E-1F72BA71EF91 | — | — | 0.776 |
| 6 | sclcMAD13022_S60.txt | — | cohortMD1 | 0.775 |
| 7 | MNG1196 | — | — | 0.771 |
| 8 | SRR13311170 | — | — | 0.770 |
| 9 | MNG966 | — | — | 0.768 |
| 10 | SRR934914 | — | — | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.515 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.471 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.395 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.375 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.372 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.362 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.323 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.287 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.284 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.273 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.263 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.238 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.219 | Inavolisib | — uncovered |
| PEROXISOME | 0.198 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.179 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.173 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.138 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.121 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.075 | Inavolisib | — uncovered |